N4 Pharma PLC Formulation Work Update (3517H)
December 03 2020 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 3517H
N4 Pharma PLC
03 December 2020
3 December 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
Formulation Work Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide the following update on its
ongoing research collaboration agreement with Nanomerics Limited
("Nanomerics").
As announced on 11 February 2020, the Company initiated the
first phase of research to test the stability of different
formulations of Nuvec(R) loaded with a well characterised plasmid
DNA. The Company is pleased to report that, in addition to not
degrading the plasmid DNA, which it announced on 5 November 2020,
Nuvec(R) formulations that had been freeze dried and then stored
for 14 days either at room temperature or at four degrees Celsius,
showed no significant drop in in vitro transfection capability
following reconstitution compared to fresh formulations.
In parallel to continued work on analysing stability duration,
different formulations will now be chosen to move forward into
phase two of the work programme testing the efficacy of the dried
and reconstituted plasmid DNA in an in vivo antibody generation
model .
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"Demonstrating that Nuvec(R) loaded with a plasmid DNA can be
dried, stored at convenient temperatures and reconstituted without
any drop in transfection is a significant step forward in our
formulation development work.
"The recent success of Pfizer and Moderna with an mRNA Covid-19
vaccine shows the potential for nucleic acid vaccines. However, it
also highlights that these vaccines have certain limitations, in
that they often require extreme storage conditions.
"Although vaccine efficacy is predominantly determined by the
selected nucleic acid antigen, having a stable, easy to store and
easy to use vaccine is crucial in helping vaccine acceptance and
uptake. A formulation stable at room temperature or even
refrigerated can represent significant cost savings in vaccine
transportation, storage and administration. We believe, to the
extent that Nuvec(R) as a delivery platform can provide a solution
in this area, it could be of significant interest to multiple
vaccine developers.
"Work will continue in this area and will add to the breadth of
proof of concept data we are building for the use of Nuvec(R) as a
delivery system for vaccines and cancer treatments."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre-clinical and clinical programs, N4
Pharma will seek to receive up-front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBCBDDUBGDGGD
(END) Dow Jones Newswires
December 03, 2020 02:00 ET (07:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024